BioSpace News Archive

FDA has granted clearance for the commencement of Phase 1 clinical trials of STI-2020 (COVI-AMG TM ) in healthy volunteers and COVID-19 patients with mild symptoms. STI-2020, a monoclonal antibody, has been engineered for ultra-high potency, which potentially translates to a smaller IV volume required to administer an effective dose. In preclinical studies, STI-2020 demonstrated strong or stronger affinities to multiple antibody drug-resistant SARS-CoV-2 variants. Outpatient trials are expect

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update on DANYELZA® (naxitamab-gqgk) for the treatment of Refractory/Relapsed High-Risk Neuroblastoma was given at the ESMO Immuno-Oncology Virtual Congress 2020, which is being held D

Bolt Biotherapeutics, a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, today announced the presentation of a poster detailing the design of its ongoing Phase 1/2 clinical trial for BDC-1001 in patients with HER2-expressing solid tum

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that new data will be presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, in an oral presentation on December 10, 2020 at the 2020 European Society for Medical Oncology Immuno-Oncology (ESMO IO) Virtual Congress

Web-based platform for fresh osteochondral allograft ordering debuts this week during the virtual 2020 Orthopedic Summit and Emerging Technologies conference Dec. 10-12.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.

Limitless Venture Group, Inc. announced it has signed a consulting agreement with Nexus Insurance Marketing Group, LLC of Austin, Tx.

-- Mino-Wrap’s novel approach to reducing post-mastectomy infections associated with the use of a tissue expander is on track in its preclinical stage -- Some next steps for Mino-Wrap development include designing and executing a large animal study and the clinical plan

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today the presentation of the latest interim data from its ongoing phase Ib combination trial of olinvacimab and pembrolizumab for metastatic triple-negative breast cancer (mTNBC) pat

Beverly MA Life Science Relocation Company in Cooperation with PHCbi Offers States More Reliable Distribution Model.